Jefferies Maintains 'Hold' Rating on Myriad Genetics (MYGN) Post Q1, Estimates Lowered

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. APGE
5. MU
6. GOOGL
7. HOOD
8. DFTX
9. USO
10. MSTR

Go back to Jefferies Maintains 'Hold' Rating on Myriad Genetics (MYGN) Post Q1, Estimates Lowered

Myriad Genetics (MYGN) Misses Q1 EPS by 7c; Maintains Outlook

November 4, 2014 4:24 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.25, $0.07 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $168.8 million versus the consensus estimate of $175 million.

Myriad Genetics sees FY2014 EPS of $1.90-$2.00, versus the consensus of $1.89. Myriad Genetics sees FY2014... More